Hims & Hers Health, Inc. Research & Development Expenses (R&D)
| Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|
| Research & Development Expenses (R&D) | $0.0 | $0.0 | $11.2M | $22.4M | $29.2M | $48.2M |
Hims & Hers Health, Inc. (HIMS) Research & Development Expenses (R&D) comparison analysis
General
LTM Research & Development Expenses (R&D)
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
HIMS key stats
| Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|
% growth | 26.7 0.0% | 82.6 209.4% | 148.8 80.2% | 271.9 82.8% | 526.9 93.8% | 872.0 65.5% |
| Cost of Goods Sold (COGS) | 18.9 | 38.0 | 39.3 | 67.4 | 118.2 | 157.1 |
% margin | 7.8 29.2% | 44.6 54.0% | 109.5 73.6% | 204.5 75.2% | 408.7 77.6% | 714.9 82.0% |
| Operating Expenses | 83.6 | 119.0 | 124.6 | 319.5 | 477.4 | 744.4 |
| Research & Development Expenses (R&D) | 0.0 | 0.0 | 11.2 | 22.4 | 29.2 | 48.2 |
| Selling, General & Administrative Expenses (SG&A) | 83.6 | 119.0 | 124.6 | 319.5 | 370.8 | 692.7 |
% margin | (75.8) (284.0%) | (74.4) (90.1%) | (15.1) (10.2%) | (115.0) (42.3%) | (68.7) (13.0%) | (29.5) (3.4%) |
| Interest Income | 0.6 | 1.9 | 0.4 | 0.4 | 2.6 | 0.0 |
| Interest Expense | 0.0 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 |
| Pre-tax Income | (75.2) | (72.0) | (18.0) | (110.8) | (65.7) | (21.6) |
% effective tax rate | 0.0 (0.0%) | 0.1 (0.1%) | 0.1 (0.7%) | (3.1) 2.8% | (0.0) 0.0% | 2.0 (9.2%) |
% margin | (75.2) (282.0%) | (72.1) (87.3%) | (18.1) (12.2%) | (107.7) (39.6%) | (65.7) (12.5%) | (23.5) (2.7%) |
| EPS | (1.12) | (2.86) | (0.51) | (0.58) | (0.32) | (0.11) |
| Diluted EPS | (1.12) | (2.86) | (0.51) | (0.58) | (0.32) | (0.11) |
% margin | 0.0 0.0% | (74.2) (89.8%) | (14.1) (9.5%) | (111.0) (40.8%) | (61.2) (11.6%) | (19.9) (2.3%) |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
FAQ
1) What is Hims & Hers Health, Inc.'s Research & Development Expenses (R&D)?
As of today, Hims & Hers Health, Inc.'s last 12-month Research & Development Expenses (R&D) is $78.8M, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is Hims & Hers Health, Inc.'s Research & Development Expenses (R&D) growth rate?
Over the last year, Hims & Hers Health, Inc.'s Research & Development Expenses (R&D) growth was 63.4%. The average annual Research & Development Expenses (R&D) growth rates for Hims & Hers Health, Inc. have been N/A over the past three years, N/A over the past five years.
3) Is Hims & Hers Health, Inc.'s Research & Development Expenses (R&D) growth rate Good?
Over the last year, Hims & Hers Health, Inc.'s Research & Development Expenses (R&D) growth was 63.4%, which is higher than industry growth of (0.9%). It indicates that Hims & Hers Health, Inc.'s Research & Development Expenses (R&D) growth is Bad.